Global professional services firm ZS (Evanston, IL) announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected CEO.
Succeeding Chris Wright, who served the firm’s maximum term as CEO, Khedkar is just the third CEO in ZS’ nearly 40-year history. Holding various leadership roles during his 21 years with the company, Khedkar has led ZS‘ global pharmaceuticals and biotechnology practice for nearly a decade, headed up the firm’s advanced data science track, and recently turned his attention to expanding the firm’s healthcare expertise to help clients establish deeper relationships and more effective partnerships across the healthcare ecosystem.
“Pratap is stepping into this role during an exciting period of growth and change at ZS,” commented Wright, who oversaw the company’s 30% growth in 2020. “We’re increasingly being called in by the companies we partner with to identify, advise on and adapt to the next big shifts in their respective industries. I’m confident that under Pratap’s counsel, the best days at ZS are ahead of us.”
Khedkar will oversee the global acceleration and scaling of ZS’ portfolio of life sciences and healthcare work. He plans to ramp up investments in the firm’s technology, digital analytics and software capabilities across healthcare and in other industries.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.